Cargando…

An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma

The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circumvent multidrug resistance. Previously, we showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Dongmei, Jiang, Linlin, Song, Yuewen, Bao, Shiqi, Yang, Yuanyuan, Yuan, Xiangfei, Zhen, Yongsu, Yang, Ming, Xiong, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737009/
https://www.ncbi.nlm.nih.gov/pubmed/31555598
http://dx.doi.org/10.3389/fonc.2019.00861
_version_ 1783450594646687744
author Fan, Dongmei
Jiang, Linlin
Song, Yuewen
Bao, Shiqi
Yang, Yuanyuan
Yuan, Xiangfei
Zhen, Yongsu
Yang, Ming
Xiong, Dongsheng
author_facet Fan, Dongmei
Jiang, Linlin
Song, Yuewen
Bao, Shiqi
Yang, Yuanyuan
Yuan, Xiangfei
Zhen, Yongsu
Yang, Ming
Xiong, Dongsheng
author_sort Fan, Dongmei
collection PubMed
description The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circumvent multidrug resistance. Previously, we showed that an engineered cytotoxic fusion protein anti-CD19(Fab)-LDM (lidamycin), can induce apoptosis of B-lymphoma cells. Herein, we successfully established an adriamycin (ADR)-resistant B cell lymphoma cell line BJAB/ADR. The mRNA and protein level of ATP-binding cassette subfamily B member 1 (ABCB1) were significantly overexpressed in BJAB/ADR cells. Increased efflux function of ABCB1 was observed by analyzing intracellular accumulation and efflux of Rhodamine 123. The efflux of Rhodamine 123 could be significantly ameliorated by verapamil. Treatment with anti-CD19(Fab)-LDM at different concentrations induced cytotoxic response of BJAB/ADR cells similar to that of the sensitive cells. In vivo studies showed that anti-CD19(Fab)-LDM had better antitumor effect in BJAB and BJAB/ADR cell lymphoma xenografts compared with ADR or LDM treatment alone. Taken together, anti-CD19(Fab)-LDM can effectively inhibit the growth of BJAB/ADR cells both in vitro and in vivo. Anti-CD19(Fab)-LDM could be a promising molecule for the treatment of drug resistant cancers.
format Online
Article
Text
id pubmed-6737009
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67370092019-09-25 An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma Fan, Dongmei Jiang, Linlin Song, Yuewen Bao, Shiqi Yang, Yuanyuan Yuan, Xiangfei Zhen, Yongsu Yang, Ming Xiong, Dongsheng Front Oncol Oncology The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circumvent multidrug resistance. Previously, we showed that an engineered cytotoxic fusion protein anti-CD19(Fab)-LDM (lidamycin), can induce apoptosis of B-lymphoma cells. Herein, we successfully established an adriamycin (ADR)-resistant B cell lymphoma cell line BJAB/ADR. The mRNA and protein level of ATP-binding cassette subfamily B member 1 (ABCB1) were significantly overexpressed in BJAB/ADR cells. Increased efflux function of ABCB1 was observed by analyzing intracellular accumulation and efflux of Rhodamine 123. The efflux of Rhodamine 123 could be significantly ameliorated by verapamil. Treatment with anti-CD19(Fab)-LDM at different concentrations induced cytotoxic response of BJAB/ADR cells similar to that of the sensitive cells. In vivo studies showed that anti-CD19(Fab)-LDM had better antitumor effect in BJAB and BJAB/ADR cell lymphoma xenografts compared with ADR or LDM treatment alone. Taken together, anti-CD19(Fab)-LDM can effectively inhibit the growth of BJAB/ADR cells both in vitro and in vivo. Anti-CD19(Fab)-LDM could be a promising molecule for the treatment of drug resistant cancers. Frontiers Media S.A. 2019-09-04 /pmc/articles/PMC6737009/ /pubmed/31555598 http://dx.doi.org/10.3389/fonc.2019.00861 Text en Copyright © 2019 Fan, Jiang, Song, Bao, Yang, Yuan, Zhen, Yang and Xiong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Fan, Dongmei
Jiang, Linlin
Song, Yuewen
Bao, Shiqi
Yang, Yuanyuan
Yuan, Xiangfei
Zhen, Yongsu
Yang, Ming
Xiong, Dongsheng
An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
title An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
title_full An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
title_fullStr An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
title_full_unstemmed An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
title_short An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
title_sort engineered fusion protein anti-cd19(fab)-ldm effectively inhibits adr-resistant b cell lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737009/
https://www.ncbi.nlm.nih.gov/pubmed/31555598
http://dx.doi.org/10.3389/fonc.2019.00861
work_keys_str_mv AT fandongmei anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT jianglinlin anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT songyuewen anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT baoshiqi anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT yangyuanyuan anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT yuanxiangfei anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT zhenyongsu anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT yangming anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT xiongdongsheng anengineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT fandongmei engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT jianglinlin engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT songyuewen engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT baoshiqi engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT yangyuanyuan engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT yuanxiangfei engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT zhenyongsu engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT yangming engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma
AT xiongdongsheng engineeredfusionproteinanticd19fabldmeffectivelyinhibitsadrresistantbcelllymphoma